Moneycontrol
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Sun Pharmaceutical Industries

Sun Pharmaceutical Industries

BSE: 524715|NSE: SUNPHARMA|ISIN: INE044A01036|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Jul 20, 10:04
547.40
2.3 (0.42%)
VOLUME 26,094
LIVE
NSE
Jul 20, 10:04
546.95
2 (0.37%)
VOLUME 379,626
News on Sun Pharmaceutical Industries
Select Year: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Sun Pharmaceuticals Q1 PAT seen up 68.7% YoY to Rs. 886.9 cr: Kotak

3.33 pm | 18 Jul 2018 |  Source: Moneycontrol.com

Net Sales are expected to increase by 14.3 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 7,096.3 crore, according to Kotak....

Sun Pharma gets USFDA nod to launch chemo drug filed from Halol site

1.18 pm | 18 Jul 2018 |  Source: Moneycontrol.com

This chemotherapy drug, called INFUGEM 10 mg/mL, is a combination of gemcitabine in 0.9% sodium chloride injection used in treatment of cancer...

Sun Pharmaceutical gains 1% on first USFDA approval from Halol plant

11.26 am | 18 Jul 2018 |  Source: Moneycontrol.com

Infugem uses a proprietary technology which allows cytotoxic oncology products to be premixed in a sterile environment and supplied to the prescribers...

Sun Pharma's unit presses more charges against Biofrontera in patent infringement case

2.58 pm | 12 Jul 2018 |  Source: Moneycontrol.com

The unit, Dusa Pharmaceuticals, was bought by Sun Pharma in 2012...

With United States trade under a cloud, China opens to Indian pharma

12.30 pm | 12 Jul 2018 |  Source: Reuters

India dominates the world's generic drugs market, exporting $17.3 billion worth of drugs in the 2017/18 (April-March) year, including to the U...

Top buy & sell ideas by Ashwani Gujral, Sudarshan Sukhani, Mitessh Thakkar for short term 

8.13 am | 04 Jul 2018 |  Source: Moneycontrol.com

Mitessh Thakkar of mitesshthakkar.com suggests buying Aurobindo Pharma with a stop loss of Rs 615 and target of Rs 646, KPIT Tech with a stop loss of ...

Buy Sun Pharma, target Rs 600: Vinay Rajani

8.41 am | 03 Jul 2018 |  Source: Moneycontrol.com

We recommend buying Sun Pharma for the upside target of Rs 600 and keep a stop loss placed at Rs 545, says Vinay Rajani of HDFC Securities....

Markets@Moneycontrol: Nifty likely to open flat; Sun Pharma, Tata Elxsi top buy ideas 

8.31 am | 03 Jul 2018 |  Source: Moneycontrol.com

Trends on SGX Nifty indicate a flat opening for the broader index in India, a rise of 5 points or 0.05 percent. Nifty futures were trading around 10,6...

Buy or sell: Top stock trading ideas by market experts which are good short term bets

8.18 am | 03 Jul 2018 |  Source: Moneycontrol.com

Rajesh Agarwal of AUM Capital recommends buying Asian Paints with stop loss at Rs 1273 and target of Rs 1315, BEML with stop loss at Rs 795 and target...

Podcast | A morning walk down Dalal Street: Stay cautious as long as Nifty trades below 10,700

7.22 am | 03 Jul 2018 |  Source: Moneycontrol.com

Analysts advise investors to remain cautious as a weakness could persist in the market as long as Nifty trades below 10660-10700 levels....

Buy Sun Pharmaceutical Industries: Equity99

2.30 pm | 25 Jun 2018 |  Source: Moneycontrol.com

The company should be able to gradually increase sales for the current portfolio, where it had lost market share. We are recommending a buy, says Sumi...

Hold Sun Pharmaceutical Industries; target of Rs 597: Geojit

3.45 pm | 21 Jun 2018 |  Source: Moneycontrol.com

Geojit recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 597 in its research report dated June 19, 2018....

Buy Sun Pharmaceutical Industries: Akash Jain

2.44 pm | 18 Jun 2018 |  Source: Moneycontrol.com

We believe Sun Pharma is the best play in pharma space and investors can add this stock in their long term portfolio, says Akash Jain of Ajcon Global....

Buy Sun Pharma, target Rs 650: Equity99

2.34 pm | 18 Jun 2018 |  Source: Moneycontrol.com

It has made superb double bottom formation at Rs 435. After a smart move in short time, stock has strong hurdle near Rs 585-605 levels. Cross over wil...

How Sun Pharma managed to get its Halol facility off the USFDA hook

1.08 pm | 16 Jun 2018 |  Source: Moneycontrol.com

Analysts estimate the upside, from Halol facility, on FY19 revenues to be in the range of USD 100-150 million with pending approvals gaining momentum...

Nervousness persist, Nifty may face resistance at 10,850 levels

8.59 am | 15 Jun 2018 |  Source: Moneycontrol.com

“The Nifty ended the session with a Hanging Man candle, which implies that nervousness still persists” says Jaydeb Dey of Stewart & Mackertich Wea...

Sun Pharma gains 3% post EIR for Halol facility; Morgan Stanley maintains underweight

9.27 am | 13 Jun 2018 |  Source: Moneycontrol.com

The company has received the EIR (establishment inspection report) from the USFDA for the inspection conducted at its Halol facility (Gujarat, India) ...

Sun Pharma gets EIR for crucial Halol plant, US sales to get boost

8.42 pm | 12 Jun 2018 |  Source: Moneycontrol.com

The EIR will allow Sun Pharma to restart supplies from the Halol facility to US, its largest market....

Sun Pharma extends gains post VAI status from US FDA on Friday, up 1%

9.34 am | 11 Jun 2018 |  Source: Moneycontrol.com

The stock has touched an intraday high of Rs 536.00 and an intraday low of Rs 527.70....

Accumulate Sun Pharmaceutical; target of Rs 539: KRChoksey

5.21 pm | 06 Jun 2018 |  Source: Moneycontrol.com

KRChoksey recommended accumulate rating on Sun Pharmaceutical with a target price of Rs 539 in its research report dated May 29, 2018....

1 2 3
Quick Links for Sun Pharmaceutical Industries
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.